CG Oncology (NASDAQ: CGON) director receives 9,354-share stock option grant

Rhea-AI Filing Summary

CG Oncology director Christina Rossi received a stock option grant covering 9,354 shares of common stock. The option has an exercise price of $56.09 per share and expires on June 3, 2036. Vesting occurs in 12 equal monthly installments after June 4, 2026, with any remaining unvested portion vesting at the next annual stockholder meeting if it occurs within the first year, subject to her continued service.

Insights

Equity compensation analyst

Routine director option grant with time-based vesting.

This Form 4 shows director Christina Rossi receiving an option to buy 9,354 shares of CG Oncology, Inc. common stock at an exercise price of $56.09 per share, expiring on June 3, 2036.

The grant is standard, time-based equity compensation: 1/12 of the option vests monthly following the June 4, 2026 grant date, with a potential acceleration at the next annual stockholder meeting. Vesting requires continuous service as a director.

Because this is a compensation award rather than an open-market purchase or sale, it typically has limited signaling value about near-term views on the stock. It does, however, increase Rossi’s long-term equity exposure to company performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rossi Christina

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	9,354	$0.00	$0.00

Holdings After Transaction: Director Stock Option (right to buy) — 9,354 shares (Direct)

Footnotes (1)

1. F1. 1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Key Figures

Option grant size: 9,354 shares Exercise price: $56.09 per share Expiration date: June 3, 2036 +3 more

6 metrics

Option grant size 9,354 shares Director stock option grant on June 4, 2026

Exercise price $56.09 per share Director stock option exercise price

Expiration date June 3, 2036 Option expiration for director grant

Post-grant derivative holdings 9,354 options Total derivative securities following transaction

Vesting start date June 4, 2026 Grant date from which monthly vesting begins

Monthly vesting fraction 1/12 of grant Portion of option vesting each month after grant date

Key Terms

Director Stock Option (right to buy), exercise price, vesting, expiration date

4 terms

Director Stock Option (right to buy) financial

"security_title: Director Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 56.0900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"subject to the Reporting Person's continuous service to the Issuer through each vesting date."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-06-03T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/05/2026 - 04:30 PM Accepted by SEC EDGAR 06/05/2026 - 04:30 PM Learn about SEC filing dates

FAQ

What did CG Oncology (CGON) director Christina Rossi report in this Form 4?

Christina Rossi reported receiving a director stock option for 9,354 CG Oncology common shares. The option is a compensation grant, not an open-market trade, giving her the right to buy shares at a fixed $56.09 exercise price before it expires in 2036.

What are the key terms of Christina Rossi’s CGON stock option grant?

Rossi’s option covers 9,354 CG Oncology shares at a $56.09 exercise price and expires June 3, 2036. It vests over time, meaning she earns the right to exercise portions gradually, subject to her continued service on the company’s board.

How does the vesting schedule work for Christina Rossi’s CGON option?

One-twelfth of the 9,354-share option vests monthly after June 4, 2026, the grant date. If CG Oncology’s next annual stockholder meeting occurs before the first anniversary, any remaining unvested portion vests that day, assuming Rossi continues in service through each vesting date.

Is Christina Rossi buying or selling CG Oncology (CGON) shares in this filing?

She is not buying or selling shares in the market; she received an option grant. The Form 4 records a compensation award giving her the right to purchase 9,354 CG Oncology shares later at $56.09, subject to vesting and her continued board service.

How many CG Oncology shares can Christina Rossi acquire from this option grant?

The grant allows her to acquire up to 9,354 CG Oncology common shares upon exercise. Actual acquisition depends on future vesting and her decision to exercise at the $56.09 price before the option’s June 3, 2036 expiration date, assuming continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rossi Christina

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

3000 PEGASUS PARK DRIVE, SUITE 1640

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$56.09	06/04/2026		A		9,354		(1)	06/03/2036	Common Stock	9,354	$0	9,354	D

Explanation of Responses:

1. 1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.

	/s/ Joshua Patterson, Attorney-in-Fact for Christina Rossi	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)